Reducing the risk of heart attack and stroke during COVID-19 - Click here

RESULTS

 

Guidelines

Guidance documents about high cholesterol and FH detection and managenent

Statin intolerance pathway

Double sided A4 summary schematic document produced by the Accelerated Access Collaborative and endorsed by NICE. 

Publication date:
June 2020
Summary of national guidance for lipid management for primary and secondary prevention of CVD

Double sided A4 summary schematic of latest guidance on lipid management from the Accelerated Access Collaborative.

Publication date:
March 2020
Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia (TA385)

Technology Appraisal Guidance from NICE

Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA 393)

Technology Appraisal Guidance from NICE

Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA394)

Techology Appraisal Guidance from NICE

Familial hypercholesterolaemia: identification and management (CG71)
Cardiovascular disease: risk assessment and reduction, including lipid modification (CG181)

Clinical Guidance from NICE

Familial hypercholesterolaemia

Cardiovascular disease: risk assessment, reduction, including lipid modification.

Familial hypercholesterolaemia: identification and management : Clinical guideline [CG71]

Familial hypercholesterolaemia: identification and management : Clinical guideline [CG71]

Published date: August 2008

Last updated: October 2019

Back to top icon Back to top